One-Shot gene therapy aims to ease burden of frequent eye injections
NCT ID NCT07178249
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 29 times
Summary
This early-phase trial tests a gene therapy called EXG202 for wet age-related macular degeneration (nAMD). The goal is to see if a single injection into the eye can safely deliver a protein that blocks abnormal blood vessel growth, potentially reducing the need for repeated anti-VEGF injections. The study will enroll 60 adults aged 50 and older with active nAMD and monitor their vision and side effects for up to a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WET AGE RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.